Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Effects of CYP3A4 Inhibition by Diltiazem on Pharmacokinetics and Dynamics of Diazepam in Relation to CYP2C19 Genotype Status

Kazuhiro Kosuge, Yang Jun, Hiroshi Watanabe, Masahiko Kimura, Masahiko Nishimoto, Takashi Ishizaki and Kyoichi Ohashi
Drug Metabolism and Disposition October 2001, 29 (10) 1284-1289;
Kazuhiro Kosuge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yang Jun
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroshi Watanabe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masahiko Kimura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masahiko Nishimoto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takashi Ishizaki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kyoichi Ohashi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Diazepam is metabolized by CYP2C19 and CYP3A4 in the liver. CYP2C19 shows genetic polymorphism associated with the poor metabolizer (PM) and extensive metabolizer (EM) phenotypes. The aim of this study was to assess the effect of diltiazem, a CYP3A4 inhibitor, on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status. Thirteen healthy volunteers (eight EMs and five PMs) were given placebo or diltiazem (200 mg) orally for 3 days before and for 7 days after the oral 2-mg dose of diazepam in a double-blind, randomized, crossover manner. The pharmacokinetics and pharmacodynamics of diazepam were assessed with and without diltiazem. Plasma concentrations and area under the plasma concentration-time curves (AUCs) of diazepam and N-desmethyldiazepam were significantly greater in the PM compared with the EM group during the placebo phase. Diltiazem significantly increased AUC and prolonged eliminationt1/2 of diazepam in both the PM and EM groups. These pharmacokinetic changes, however, caused no significant difference in the pharmacodynamics between the two trial phases. Diltiazem affects the pharmacokinetics of diazepam in the PM and EM groups of CYP2C19. Inhibition of CYP3A4 by a concomitant substrate drug like diltiazem may cause a pharmacokinetic interaction with diazepam irrespective of CYP2C19 genotype status, but whether this interaction would reflect a pharmacodynamic change of diazepam remains unconfirmed by our study.

Footnotes

  • This study was supported by grants-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology and the Japan Research Foundation for Clinical Pharmacology, Tokyo, Japan (K.K., Y.J., H.W., M.K., M.N., K.O.) and by a grant-in-aid from the Organization of Pharmaceutical Safety and Research (OPSR) (T.I.), Tokyo, Japan.

  • Abbreviations used are::
    PM
    poor metabolizer
    wt
    wild-type
    m1
    mutation in exon 5
    m2
    mutation in exon 4
    EM
    extensive metabolizer
    HPLC
    high-pressure liquid chromatography
    AUC
    area under the plasma concentration-time curve
    • Received April 18, 2001.
    • Accepted July 17, 2001.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 29 (10)
Drug Metabolism and Disposition
Vol. 29, Issue 10
1 Oct 2001
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Effects of CYP3A4 Inhibition by Diltiazem on Pharmacokinetics and Dynamics of Diazepam in Relation to CYP2C19 Genotype Status
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Effects of CYP3A4 Inhibition by Diltiazem on Pharmacokinetics and Dynamics of Diazepam in Relation to CYP2C19 Genotype Status

Kazuhiro Kosuge, Yang Jun, Hiroshi Watanabe, Masahiko Kimura, Masahiko Nishimoto, Takashi Ishizaki and Kyoichi Ohashi
Drug Metabolism and Disposition October 1, 2001, 29 (10) 1284-1289;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Effects of CYP3A4 Inhibition by Diltiazem on Pharmacokinetics and Dynamics of Diazepam in Relation to CYP2C19 Genotype Status

Kazuhiro Kosuge, Yang Jun, Hiroshi Watanabe, Masahiko Kimura, Masahiko Nishimoto, Takashi Ishizaki and Kyoichi Ohashi
Drug Metabolism and Disposition October 1, 2001, 29 (10) 1284-1289;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Ozanimod human metabolism and Disposition
  • High-throughput Characterization of SLCO1B1 Variants of VUS.
  • Poria cocos triterpenes as bile acid transporter inhibitors
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics